The test, which received FDA clearance in late 2017, runs in as little as 18 minutes.
The firm showed 98 percent sensitivity and 100 percent specificity across all major HCV genotypes in a recent study.
Investigators and commercial firms presenting at the recent AACR meeting highlighted how heterogeneous both the technology and the application of liquid biopsy remains.
The firm saw modest growth in both its life science and diagnostics divisions and increased its guidance for the year.
The assay could provide detection of HBV infection at early stages, potentially preventing progression to cirrhosis or hepatocellular carcinoma.
The company submitted the platform and gastrointestinal panel to the US Food and Drug Administration for clearance earlier this year.
NuProbe said it will use the funding to expand its staff and to continue development of its toehold hybridization probe technology.
The company unveiled forthcoming products for high-throughput molecular testing, diagnostic lab informatics, and microbiology automation.
The exclusive deal includes sales and marketing of a rapid thermal cycler as well as consumable microplates and pipette tips.
The deal covers SpeeDx's line of multiplexed PlexPCR and ResistancePlus tests in the UK and Ireland.
The approval expands the firm's product range now available to European customers.
The workflow was launched along with a menu of infectious disease detection kits, including assays for cytomegalovirus, Epstein-Barr virus, BK virus, and parvovirus.
The five-year-old firm recently completed a clinical trial of the real-time PCR-based test, called ProALL-BM, on patients from a European National Registry Study.
The partnership will allow Serosep's customers to benefit from standardized diagnostic interpretation supported by artificial intelligence and automation.
Sales were driven by a strong flu season and growth in Asia-Pacific business.
The FDA approved its use with tissue or plasma biopsies, giving clinicians a non-invasive option to conduct a test that provides results in a day.
The test cartridge runs on the company's Unyvero platform and covers 103 diagnostic targets for various pathogens and markers of antibiotic resistance.
Isoma, which launched last year, will use the funds to develop and clinically validate a molecular test for stratifying glioblastoma patients.
The firm said that its Cobas CT/NG real-time PCR assay is the first available in the US for the testing of sexually transmitted infections on its 6800 and 8800 systems.
The team plans to eventually implement the MSI test clinically to determine whether patients are eligible for immunotherapy.
US News & World Report writes that genetic testing of lung tumors can help identify treatments for patients.
A team of researchers plans to sample Loch Ness for environmental DNA, according to Newsweek.
The New York Times writes about the appearance of mosaicism in healthy people.
In PNAS this week: insecticide resistance patterns Anopheles gambiae mosquito, transcriptome patterns in Pseudomonas aeruginosa during infection, and more.